A thematic analysis of prognostic, diagnostic, and therapeutic of circulating miRNA biomarkers in bortezomib-resistant multiple myeloma

Objective: The increasing demand for precision medicine has spurred molecular diagnostic investigations to emphasize the utility of miRNA as significant biomarkers. Recent studies have underscored miRNA’s role as prognostic, diagnostic, and therapeutic biomarkers in managing and monitoring multiple...

Full description

Saved in:
Bibliographic Details
Main Authors: Shafisha Bamfield-Cummings, Jeane Silva, Zubair A. Karim
Format: Article
Language:English
Published: SAGE Publishing 2025-04-01
Series:SAGE Open Medicine
Online Access:https://doi.org/10.1177/20503121251328486
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850196483958112256
author Shafisha Bamfield-Cummings
Jeane Silva
Zubair A. Karim
author_facet Shafisha Bamfield-Cummings
Jeane Silva
Zubair A. Karim
author_sort Shafisha Bamfield-Cummings
collection DOAJ
description Objective: The increasing demand for precision medicine has spurred molecular diagnostic investigations to emphasize the utility of miRNA as significant biomarkers. Recent studies have underscored miRNA’s role as prognostic, diagnostic, and therapeutic biomarkers in managing and monitoring multiple myeloma patients. This review aims to present the latest insights on the potential of circulating miRNA as prognostic, diagnostic, and therapeutic biomarkers in bortezomib-resistant multiple myeloma. Methods: For this purpose, a comprehensive thematic literature review from January 2014 and August 2024 was conducted utilizing the databases CINAHL, Pubmed, and Google Scholar. Twenty pertinent studies were meticulously analyzed and categorized into the following sections: Bortezomib (BTZ) resistance in multiple myeloma, the predictive role of miRNAs in BTZ resistance, the impact of circulating miRNAs in multiple myeloma, and the potential of circulating miRNA as prognostic, diagnostic, and therapeutic biomarkers. Results: Of note, eight studies identified circulating miRNAs as diagnostic miRNA biomarkers (i.e., miR-744, miR-130a, let-7d, let-7e, miR-34a, etc.). In comparison, nine studies identified several circulating miRNAs that can be used as prognostic biomarkers (i.e., miR-20a, miR-483-5p, mir-1246, let-7a, let-7e, etc.). Moreover, five studies identified circulating miRNAs as promising therapeutic biomarkers (i.e., mir-15a, mir-92a, mir-19a, etc.). This discovery can significantly enhance early detection, accurate diagnosis, prognosis, overall survival rates, and quality of life for patients with multiple myeloma. Conclusion: Based on this evidence, exploring circulating miRNAs as a potential noninvasive biomarker for multiple myeloma represents a noteworthy advancement. This is attributed to the abundance of miRNAs in plasma or serum, which exhibits remarkable stability against enzymatic degradation.
format Article
id doaj-art-b7d5be3c683d4e189c81a7297c7b51fa
institution OA Journals
issn 2050-3121
language English
publishDate 2025-04-01
publisher SAGE Publishing
record_format Article
series SAGE Open Medicine
spelling doaj-art-b7d5be3c683d4e189c81a7297c7b51fa2025-08-20T02:13:27ZengSAGE PublishingSAGE Open Medicine2050-31212025-04-011310.1177/20503121251328486A thematic analysis of prognostic, diagnostic, and therapeutic of circulating miRNA biomarkers in bortezomib-resistant multiple myelomaShafisha Bamfield-Cummings0Jeane Silva1Zubair A. Karim2Department of Health Management, Economics, and Policy, Augusta University, GA, USADepartment of Health Management, Economics, and Policy, Augusta University, GA, USADepartment of Nutrition and Dietetics, College of Allied Health Science, Augusta University, GA, USAObjective: The increasing demand for precision medicine has spurred molecular diagnostic investigations to emphasize the utility of miRNA as significant biomarkers. Recent studies have underscored miRNA’s role as prognostic, diagnostic, and therapeutic biomarkers in managing and monitoring multiple myeloma patients. This review aims to present the latest insights on the potential of circulating miRNA as prognostic, diagnostic, and therapeutic biomarkers in bortezomib-resistant multiple myeloma. Methods: For this purpose, a comprehensive thematic literature review from January 2014 and August 2024 was conducted utilizing the databases CINAHL, Pubmed, and Google Scholar. Twenty pertinent studies were meticulously analyzed and categorized into the following sections: Bortezomib (BTZ) resistance in multiple myeloma, the predictive role of miRNAs in BTZ resistance, the impact of circulating miRNAs in multiple myeloma, and the potential of circulating miRNA as prognostic, diagnostic, and therapeutic biomarkers. Results: Of note, eight studies identified circulating miRNAs as diagnostic miRNA biomarkers (i.e., miR-744, miR-130a, let-7d, let-7e, miR-34a, etc.). In comparison, nine studies identified several circulating miRNAs that can be used as prognostic biomarkers (i.e., miR-20a, miR-483-5p, mir-1246, let-7a, let-7e, etc.). Moreover, five studies identified circulating miRNAs as promising therapeutic biomarkers (i.e., mir-15a, mir-92a, mir-19a, etc.). This discovery can significantly enhance early detection, accurate diagnosis, prognosis, overall survival rates, and quality of life for patients with multiple myeloma. Conclusion: Based on this evidence, exploring circulating miRNAs as a potential noninvasive biomarker for multiple myeloma represents a noteworthy advancement. This is attributed to the abundance of miRNAs in plasma or serum, which exhibits remarkable stability against enzymatic degradation.https://doi.org/10.1177/20503121251328486
spellingShingle Shafisha Bamfield-Cummings
Jeane Silva
Zubair A. Karim
A thematic analysis of prognostic, diagnostic, and therapeutic of circulating miRNA biomarkers in bortezomib-resistant multiple myeloma
SAGE Open Medicine
title A thematic analysis of prognostic, diagnostic, and therapeutic of circulating miRNA biomarkers in bortezomib-resistant multiple myeloma
title_full A thematic analysis of prognostic, diagnostic, and therapeutic of circulating miRNA biomarkers in bortezomib-resistant multiple myeloma
title_fullStr A thematic analysis of prognostic, diagnostic, and therapeutic of circulating miRNA biomarkers in bortezomib-resistant multiple myeloma
title_full_unstemmed A thematic analysis of prognostic, diagnostic, and therapeutic of circulating miRNA biomarkers in bortezomib-resistant multiple myeloma
title_short A thematic analysis of prognostic, diagnostic, and therapeutic of circulating miRNA biomarkers in bortezomib-resistant multiple myeloma
title_sort thematic analysis of prognostic diagnostic and therapeutic of circulating mirna biomarkers in bortezomib resistant multiple myeloma
url https://doi.org/10.1177/20503121251328486
work_keys_str_mv AT shafishabamfieldcummings athematicanalysisofprognosticdiagnosticandtherapeuticofcirculatingmirnabiomarkersinbortezomibresistantmultiplemyeloma
AT jeanesilva athematicanalysisofprognosticdiagnosticandtherapeuticofcirculatingmirnabiomarkersinbortezomibresistantmultiplemyeloma
AT zubairakarim athematicanalysisofprognosticdiagnosticandtherapeuticofcirculatingmirnabiomarkersinbortezomibresistantmultiplemyeloma
AT shafishabamfieldcummings thematicanalysisofprognosticdiagnosticandtherapeuticofcirculatingmirnabiomarkersinbortezomibresistantmultiplemyeloma
AT jeanesilva thematicanalysisofprognosticdiagnosticandtherapeuticofcirculatingmirnabiomarkersinbortezomibresistantmultiplemyeloma
AT zubairakarim thematicanalysisofprognosticdiagnosticandtherapeuticofcirculatingmirnabiomarkersinbortezomibresistantmultiplemyeloma